As of November 6, 2026, Erasca, Inc. is a publicly traded company (Nasdaq: ERAS); its largest reported holder is Jonathan E. Lim, with 10.4% on Schedule 13G/A of August 14, 2026, then T. Rowe Price (6.8%). The largest insider holding is David M. Chacko, the chief financial officer and cbo, with 279,980 shares (0.08% of shares outstanding), per Form 4 of January 30, 2026 (Schedule 13G/A, August 14, 2026).
Is this your company?
About to sign with, pay or invest in Erasca, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Erasca, Inc. a real, registered company?
- Erasca, Inc. files with the SEC under CIK 1761918 (its SEC filings).
- Its shares are listed under the ticker ERAS on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in San Diego, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Erasca, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is Charles S. Fuchs, President (Form 8-K filed 2026-08-10). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Jonathan E. Lim (filed 2026-08-14).
Who are Erasca, Inc.'s owners and officers?
Erasca, Inc.: incorporated in Delaware; business address in San Diego, California; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-08-14).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-08-14 | Jonathan E. Lim | 10.4% |
| Schedule 13G, 2026-05-15 | Rtw Investments, LP | 5.2% |
| Schedule 13G/A, 2026-05-15 | Paradigm Biocapital Advisors LP | 3.3% |
| Schedule 13G/A, 2026-05-15 | T. Rowe Price Investment Management, Inc. | 6.8% |
| Schedule 13G/A, 2026-05-15 | Venrock Healthcare Capital Partners Iii, L.P. | 5.3% |
| Schedule 13G/A, 2026-05-12 | Suvretta Capital Management, LLC | 1.1% |
| Schedule 13G/A, 2026-02-17 | T. Rowe Price Investment Management, Inc. | 5.7% |
| Schedule 13G, 2026-01-14 | Paradigm Biocapital Advisors LP | 5.3% |
| Schedule 13G/A, 2025-11-14 | Logos Global Management LP | 4.8% |
| Schedule 13G, 2025-08-14 | Logos Global Management LP | 5.3% |
| Schedule 13G/A, 2025-08-14 | T. Rowe Price Investment Management, Inc. | 7.2% |
| Schedule 13G/A, 2025-08-14 | Frazier Life Sciences Public Fund, L.P. | 5.3% |
Questions about who owns Erasca, Inc.
Who owns Erasca, Inc.?
On this page, 5 holders' latest ownership filings report 5% or more of Erasca, Inc.: Jonathan E. Lim (10.4%, Schedule 13G/A, filed 2026-08-14), T. Rowe Price Investment Management, Inc. (6.8%, Schedule 13G/A, filed 2026-05-15), Venrock Healthcare Capital Partners Iii, L.P. (5.3%, Schedule 13G/A, filed 2026-05-15), Frazier Life Sciences Public Fund, L.P. (5.3%, Schedule 13G/A, filed 2025-08-14) and Rtw Investments, LP (5.2%, Schedule 13G, filed 2026-05-15).
Who are the largest shareholders of Erasca, Inc.?
By the share each holder's latest filing reports, the largest holders of Erasca, Inc. on this page are Jonathan E. Lim (10.4%), T. Rowe Price Investment Management, Inc. (6.8%) and Venrock Healthcare Capital Partners Iii, L.P. (5.3%).
When did Jonathan E. Lim buy into Erasca, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Jonathan E. Lim on this page is the Schedule 13G/A, filed 2026-08-14, reporting 10.4%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Erasca, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Erasca, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Erasca, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
17 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-08-10 | Charles S. Fuchs | President | appointed | 2026-08-10 |
Which insiders own Erasca, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief financial officer and cbo: 279,980 shares (0.08% of shares outstanding) (Form 4, 2026-01-30).
- , a director: 172,866 shares (0.05% of shares outstanding), 166,666 held directly and 6,200 indirectly (Form 4, 2025-06-03).
- , the chief legal officer: 25,076 shares (0.01% of shares outstanding) (Form 4, 2026-04-03).
Shares outstanding: 349,762,035 as of 2026-08-04, from the company's latest SEC cover page.
How much has Erasca, Inc. raised?
No fundraising or offering filing from Erasca, Inc. is on file with us.
Keep reading
More on Erasca, Inc. and the records around it.
Erasca, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Leadership changes Aug 2026
Companies that share a holder
- Logos Global Management LP also filed stake reports on 14 other companies: Longeveron Inc. (Sep 2026), ACHIEVE LIFE SCIENCES, INC. (Aug 2026), Yarrow Bioscience, Inc. (Aug 2026)
- Paradigm BioCapital Advisors LP also filed stake reports on 22 other companies: Obsidian Therapeutics, Inc. (Oct 2026), Spyre Therapeutics, Inc. (Oct 2026), Tyra Biosciences, Inc. (Sep 2026)
- Suvretta Capital Management, LLC also filed stake reports on 22 other companies: Veradermics, Inc (Aug 2026), Abeona Therapeutics Inc. (Aug 2026), Fulcrum Therapeutics, Inc. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/erasca